BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
6/11/2021 9:22:19 AM | Browse: 729 | Download: 2082
Publication Name World Journal of Clinical Cases
Manuscript ID 63794
Country Portugal
ISSN 2307-8960 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright © The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Oncology
Manuscript Type Case Report
Article Title Long-term response to avelumab and management of oligoprogression in Merkel cell carcinoma: A case report
Manuscript Source Unsolicited Manuscript
All Author List Inês Leão, Joana Marinho and Telma Costa
ORCID
Author(s) ORCID Number
Inês Leão http://orcid.org/0000-0002-6586-4980
Joana Marinho http://orcid.org/0000-0003-3665-4666
Telma Costa http://orcid.org/0000-0002-9625-1124
Funding Agency and Grant Number
Corresponding Author Telma Costa, MD, Doctor, Doctor, Department of Oncology, Centro Hospitalar Vila Nova de Gaia/Espinho, Rua Conceição Fernandes, Vila Nova de Gaia 4434-502, Portugal. telma.r.c.costa@gmail.com
Key Words Merkel cell carcinoma; Unresectable tumor; Avelumab; Oligoprogression; Surgery; Chemotherapy; Case report
Core Tip This report highlights the efficacy and long-term response of avelumab, on the management of a chemotherapy resistant advanced Merkel cell carcinoma (MCC). It shows also a successful approach to oligoprogression with local radical treatment, surgery and radiotherapy, while maintaining systemic therapy with avelumab. The results support the effectiveness of this strategy for the management of unresectable MCC.
Publish Date 2021-06-11 09:22
Citation Leão I, Marinho J, Costa T. Long-term response to avelumab and management of oligoprogression in Merkel cell carcinoma: A case report. World J Clin Cases 2021; 9(18): 4829-4836
URL https://www.wjgnet.com/2307-8960/full/v9/i18/4829.htm
DOI https://dx.doi.org/10.12998/wjcc.v9.i18.4829
Full Article (PDF) WJCC-9-4829.pdf
Full Article (Word) WJCC-9-4829.docx